Document is current

Article History

Received: 28 October 2023

Accepted: 30 November 2023

First Online: 13 December 2023

Declarations

:

: Not applicable.

: Not applicable.

: BR reports personal fees from Abbvie, Eli Lilly, Lundbeck, Novartis and Teva for participating in advisory boards and/or speaker activities as well as research funding from Novartis.SJC reports personal fees from Korea Otsuka Pharmaceutical, Boryung Pharmaceutical Co.,Ltd., Pfizer Ltd, Yuyu Pharmaceutical Company, Eli Lilly and Company, Allergan Korea, Abbvie Inc, SK chemicals, Teva-Handok company, Hyundaipharm. Co. Ltd, and H. Lundbeck A/S (Lundbeck) for advisory boards and speaker activities as well as research funding from Biohaven Asia Pacific Ltd, Allergan Korea, Abbvie Inc., Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company, Hyundaipharm. Co. Ltd,, SK chemicals, Teva-Handok company, and Lundbeck A/S (Lundbeck).RDI reports personal fees from Eli Lilly, TEVA, Lundbeck for speaker activities.ALR has no conflict of interest.DO has no conflict of interest.RO reports personal fees from Abbvie, Eli Lilly, Novartis, Pfizer, and Teva for advisory boards and speaker activities and non-financial support from Novartis and Teva.ERB has no conflict of interest.RR reports travel grants and/or honoraria for lectures or advisory boards from Allergan/AbbVie, Hormosan, Lilly, Lundbeck, Novartis and Teva.MWP reports personal fees from Abbvie, Pfizer and Teva for speaker activities.RM reports personal fees from Eli-Lilly for participating in advisory boards and speaker activities.FP reports personal fees from TEVA for speaker activities.